Immunotherapy is the treatment of disease by inducing,
enhancing, or suppressing an immune response. Cancer immunotherapy attempts to
stimulate the immune system to reject or destroy tumors. The efficacy of immunotherapy
is enhanced by nearly 30 percent when combined with conventional cancer
There are a wide variety of immunotherapies that work in different ways to either boost the body’s immune system or train the immune system to attack cancer cells, including:
Dana-Farber/Boston Children's Cancer and Blood Disorders Center is a certified treatment center for providing the FDA-approved CAR T-cell therapy called KYMRIAH for relapsed B-cell acute lymphoblastic leukemia (ALL). This promising treatment entails genetic engineering of the patient’s own T-cells to increase targeting of a specific leukemia protein and then accelerate killing of the target. After modification, they are returned to the patient via IV where they can immediately begin destroying circulating cancer cells.
Dana-Farber/Boston Children's is a leader in innovative therapies, such as immunotherapy, for a wide range of conditions. Our physicians work continuously to translate laboratory findings into clinical therapies, including examining biological therapies that help the body’s immune system fight cancer and lessen the harmful side effects
of some treatments. We are conducting clinical trials of monoclonal antibody therapy for recurrent or refractory high-risk neuroblastoma and for other advanced or refractory solid
Dana-Farber/Boston Children's is also at the forefront of pediatric cancer vaccine therapy. We participate in numerous clinical trials and have access to a vigorous
program of scientific discovery, preclinical vaccine development, and clinical
One of our vaccine therapy clinical trials targets neuroblastoma, a cancerous tumor that forms in nerve tissue of infants and young children. Through a collaboration with Penn State Hershey Medical Center, our physician/scientists have discovered in preclinical models that vaccine therapy can be successful in treating neuroblastoma and sarcoma. A phase I trial is currently underway to determine the vaccine’s safety and effectiveness in treating children with neuroblastoma and sarcomas.
Not only are we the top cancer and blood disorders center; we're also the top pediatric hospital. Above, our physicians explain how our vast clinical resources benefit patients.